Long‐term outcome of vertically acquired and post‐transfusion hepatitis C infection in children

Rerksuppaphol, Sanguansak; Hardikar, Winita; Dore, Gregory J.

doi:10.1111/j.1440-1746.2004.03463.x

Cited by 59 publications

(48 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, in our study no correlation between the mode of transmission of infection and the severity of histopathological changes in the liver was found, which is in agreement with the observations of other authors [18,29]. However, in our study group, children who acquired the infection vertically differed significantly from the group with horizontal transmission with respect to the age at infection acquisition and the age at liver biopsy (8.6 ±2.5 vs. 11.5 ±3.7 years, p = 0.02), but not according to the duration of infection.…”

Section: Considering a Strong Correlation Between Alt And Ast (R = 0supporting

confidence: 93%

Determinants of liver disease progression in children with chronic hepatitis C virus infection

Pokorska‐Śpiewak¹,

Kowalik-Mikołajewska²,

Aniszewska³

et al. 2015

pjp

View full text Add to dashboard Cite

Section: Considering a Strong Correlation Between Alt And Ast (R = 0supporting

confidence: 93%

Determinants of liver disease progression in children with chronic hepatitis C virus infection

Pokorska‐Śpiewak¹,

Kowalik-Mikołajewska²,

Aniszewska³

et al. 2015

pjp

View full text Add to dashboard Cite

“…6,17 Anecdotal reports and clinical experience suggest that this disease has a benign course during the first two decades of life, but it is still unclear whether the natural history of HCV infection in infants is similar to that in adults.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Long-term Follow-up Study of Children with Vertically Acquired Hepatitis C Virus Infection

et al. 2006

View full text Add to dashboard Cite

Seventeen children with vertically acquired hepatitis C virus (HCV) infection were followed from birth for a mean of 104 months. Alanine aminotransferase (ALT) levels were increased significantly at 3 and 6 months of age but were stable thereafter. HCV polymerase chain reaction was positive at 3 months in 16 patients and at 12 months in one patient. Viral load remained stable during followup at a mean value of 5.4 ± 0.4 log 10 . Mild chronic hepatitis was the most common histopathological feature on liver biopsy, occurring in six of the seven children biopsied at a mean age of 4.0 ± 2.4 years. Genotype did not seem to be related to the type of liver involvement. The results of this study suggest that vertically acquired HCV infection has a benign course in children, despite the presence of viraemia and persistent alterations in ALT levels.

show abstract

“…Age at infection affects prognosis [76,77] . Slower progression of the disease, at least during the first 1-2 decades, is observed in children [78] and females when infected at a young age [79] . A study by Yosry et al [80] was conducted on Egyptian children aged 317 years with chronic HCV on the relationship between HLA class Ⅱ with clinical chemical and histopathological state in that special population.…”

Section: Chronic Hcv -Disease Progressionmentioning

confidence: 99%

Hepatitis C genotype 4: The past, present, and future

Abdel-Ghaffar

Sira

Naghi

2015

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% (15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Europe. GT-4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt. In underdeveloped countries, risk factors associated with HCV infection may be due to unsafe medical practices or other factors such as familial transmission, mother's HCV status, or illiteracy. HCV prevention and control programs should include health education, increased community awareness towards the disease, controlling infection distribution in healthcare centers, proper sterilization of medical and dental instruments, and ensuring safe supply of blood and blood-products. Response rates to a 48-wk combined pegylated-interferon (PEG-IFN) and ribavirin (RBV) treatment range from 40%-69%, and HCV-GT-4 has been considered better than GT-1 but worse than GT-2 and GT-3 in treatment with PEG-IFN/RBV. However, with the introduction of the HCV-GT-1 effective protease inhibitors boceprevir and telaprevir in 2011, HCV-GT-4 became the "most difficult (GT) to treat". Recently, the direct-acting antivirals (DAAs) with pan-genotypic activities simeprevir, sofosbuvir, and daclatasvir have been recommended in triple regimens with PEG-IFN/RBV for the treatment of HCV-GT-4. An IFN-free regimen will be available for treatment of all genotypes of HCV in the near future. To date, several DAAs have been developed and are currently being evaluated in various combinations in clinical trials. As new regimens and new agents are being approved by the Food and Drug Administration, we can expect the guidelines for HCV treatment to be changed. The availability of shorter, simpler, and more tolerable treatment regimens can reduce the morbidity and mortality associated with HCV infection. With such a large number of therapeutic agents available, we can end up with a range of choices that we can select from to treat patients.

show abstract

Long‐term outcome of vertically acquired and post‐transfusion hepatitis C infection in children

Cited by 59 publications

References 31 publications

Determinants of liver disease progression in children with chronic hepatitis C virus infection

Determinants of liver disease progression in children with chronic hepatitis C virus infection

Longitudinal Long-term Follow-up Study of Children with Vertically Acquired Hepatitis C Virus Infection

Hepatitis C genotype 4: The past, present, and future

Contact Info

Product

Resources

About